The International Panel on Diagnosis of Multiple Sclerosis is considering potential revisions to its 2017 McDonald criteria for the diagnosis of multiple sclerosis, but no formal changes are expected soon, according to Dr. Jeffrey Cohen at the ACTRIMS lecture presented at the 28th European Charcot Foundation meeting, November 25, 2020.
Latest News
The Year in Review – virtual EBM and SPMS
December 2, 2020The year 2020 will be remembered for virtual visits and virtual congresses. It was also a year of the Food and Drug Administration adopting what might be termed virtual evidence-based medicine (EBM).
Ozanimod vs. fingolimod: is there a difference?
November 13, 2020A new analysis suggests that ozanimod (Zeposia) may have a better safety profile than fingolimod despite being similar agents (Swallow et al. J Comp Eff Res 2020;9:275-285). Both drugs are sphingosine-1-phosphate (S1P) receptor agonists that act as functional antagonists, sequestering T cells in secondary lymphoid organs. Fingolimod acts on S1PR-1,3,4,5, whereas ozanimod (like siponimod) is selective to S1PR1,5. Ozanimod was approved in Canada for the treatment of relapsing MS in October 2020.
B cell-directed therapies in MS – POST-ECTRIMS SPECIAL REPORT
October 23, 2020Part 2
Two anti-CD20 therapies (rituximab, ocrelizumab) are currently used for the treatment of multiple sclerosis and one, ofatumumab, is in late-stage development. Part 1 of this series examined the role of B cells in MS (see Update on B cells in MS pathophysiology, NeuroSens, June 29, 2020). Part 2 will summarize the data on the use of anti-CD20 agents in MS. Read More